November 30, 1999 in News from Our Companies

Biofiscia Closes On $2.3 Million

Post placeholder image

ATDC member company Biofisica has obtained a commitment of $2.3 million in financing.  The round was led by Unilever Technology Ventures, Novartis Venture Funds, the ATDC Seed Capital Fund, and a number of private investors. 

The funding will support Biofisica’s continued chronic wound care therapy marketing efforts in the UK and ongoing planning initiatives in the U.S.  Blount Swain has joined the company as CEO. Blount’s prior experience with early stage companies in general and his relevant tenure with Closure Medical (now part of Johnson & Johnson) in particular makes a great addition to the Biofiscia team as they continue to grow and build a successful venture.

By browsing this website, you agree to our privacy policy.
I Agree